AUPH Q2 2024 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$57M+37.8% YoY

Gross Profit

$48M84.4% margin

Operating Income

-$2M-2.6% margin

Net Income

$722,0001.3% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+13.7%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$524M

Total Liabilities

$159M

Stockholders' Equity

$365M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$41M	+37.8%
Gross Profit	$48M	$40M	+20.9%
Operating Income	-$2M	-$16M	+90.6%
Net Income	$722,000	-$11M	+106.3%

Revenue Segments

Product

$55M96%

License, Royalty and Collaboration Revenue

$2M4%